Myositis an evolving spectrum of disease

Area of Science:

• Rheumatology
• Immunology
• Neurology

Background:

• Idiopathic inflammatory myopathies (IIMs) are heterogeneous muscle disorders with traditional classifications having limitations.
• Clinical features and treatment responses vary significantly within current IIM subgroups.
• Recent identification of novel autoantibodies presents an opportunity for improved classification.

Purpose of the Study:

• To explore the potential of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in reclassifying IIMs.
• To investigate how autoantibodies can create more homogeneous patient groups.
• To determine if autoantibodies can identify IIM subsets with non-muscular symptoms and aid in prognostic stratification.

Main Methods:

• Identification and characterization of novel autoantibodies in patients with IIMs.
• Analysis of the association between specific autoantibodies (MSAs and MAAs) and clinical features.
• Evaluation of autoantibody presence in IIM subsets with predominant skin, arthritis, or interstitial lung disease manifestations.

Main Results:

• Myositis-specific autoantibodies (MSAs) are rarely found together in a single patient, allowing for distinct subgrouping.
• Each identified autoantibody is frequently linked to specific clinical presentations within IIMs.
• MSAs can identify IIM subsets lacking muscle symptoms, such as those with prominent skin, arthritis, or interstitial lung disease.
• Certain autoantibodies are associated with severe outcomes like cancer or rapidly progressive interstitial lung disease, aiding prognostic stratification.

Conclusions:

• Novel autoantibodies, particularly MSAs, offer a promising new approach to classifying idiopathic inflammatory myopathies.
• This autoantibody-based classification can lead to more homogeneous patient groups with predictable clinical features.
• Autoantibodies can identify IIM subsets with extra-muscular manifestations and provide valuable prognostic information, including cancer risk.